- Home
- ESQ vs SLS Comparison
ESQ vs SLS Comparison
Compare ESQ & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ESQ | SLS |
|---|---|---|
| Founded | 2006 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 941.0M | 924.5M |
| IPO Year | 2017 | 2007 |
Fundamental Metrics
Financial Performance| Metric | ESQ | SLS |
|---|---|---|
| Price | $109.72 | $9.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $120.33 | $10.00 |
| AVG Volume (30 Days) | 77.0K | ★ 8.7M |
| Earning Date | 04-23-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.76% | N/A |
| EPS Growth | 14.20 | ★ 50.00 |
| EPS | ★ 1.40 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $35.15 | N/A |
| Revenue Next Year | $39.09 | $110.98 |
| P/E Ratio | $78.29 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $87.54 | $1.39 |
| 52 Week High | $119.86 | $9.24 |
Technical Indicators
Market Signals| Indicator | ESQ | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 52.13 | 72.63 |
| Support Level | $103.31 | $3.72 |
| Resistance Level | $111.41 | N/A |
| Average True Range (ATR) | 2.81 | 0.88 |
| MACD | 0.36 | 0.24 |
| Stochastic Oscillator | 58.02 | 95.58 |
Price Performance
Historical ComparisonAbout ESQ Esquire Financial Holdings Inc.
Esquire Financial Holdings Inc is a financial holding company operating as a full service commercial bank. It serves the financial needs of the litigation industry and small businesses nationally, as well as commercial and retail customers in the New York metropolitan area. The bank offers tailored financial and payment processing solutions to the litigation community and their clients as well as dynamic and flexible payment processing solutions to small business owners. It operates in one operating segment, that of community banking.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.